Veru (NASDAQ:VERU) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Veru (NASDAQ:VERU) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other brokerages have also recently weighed in on VERU. Oppenheimer reissued an “outperform” rating on shares of Veru in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group started coverage on shares of Veru in a research note on Thursday, December 18th. They set a “buy” rating and a $25.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Veru Price Performance

Shares of NASDAQ:VERU opened at $2.53 on Friday. The company has a 50 day moving average of $2.43 and a 200-day moving average of $3.29. Veru has a one year low of $2.10 and a one year high of $7.40. The stock has a market cap of $40.61 million, a price-to-earnings ratio of -1.15 and a beta of -1.42.

Veru (NASDAQ:VERU) last issued its earnings results on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter in the prior year, the firm posted ($0.28) EPS. Equities research analysts anticipate that Veru will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Veru

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Catalyst Funds Management Pty Ltd acquired a new position in shares of Veru during the 2nd quarter worth $36,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Veru during the third quarter valued at $38,000. Allworth Financial LP bought a new position in Veru during the 2nd quarter worth $45,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Veru in the third quarter worth approximately $47,000. Finally, XTX Topco Ltd acquired a new position in shares of Veru in the 2nd quarter worth approximately $49,000. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.